ADA WANG: Open Payments
NPI 1952757973 · BOLINGBROOK, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,252 in 34 payments from 9 companies in 2025. Trend: 2023 $2,179 · 2024 $1,926 · 2025 $1,252
Food & beverage: $1,252
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $292 |
| Otsuka America Pharmaceutical, Inc. | 7 | $260 |
| ABBVIE INC. | 9 | $212 |
| Alkermes, Inc. | 4 | $180 |
| Neurocrine BioSciences, Inc. | 2 | $151 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $27 |
Products named: CAPLYTA, REXULTI, VRAYLAR, INGREZZA, LYBALVI, ARISTADA, SPRAVATO, Auvelity.
Industry payments across IL — which companies pay providers there.
